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Abstract 
Dibenzo[def,p]chrysene (DBC) is the most carcinogenic polycyclic aromatic hydrocarbon 
(PAH) examined to date. We investigated the immunotoxicity of DBC, manifested as spleen 
atrophy following acute exposure of adult Muta™Mouse males by oral gavage. Mice were 
exposed to 0, 2.0, 6.2, or 20.0 mg DBC /kg-bw per day, for three days. Genotoxic endpoints 
(DBC-DNA adducts and lacZ mutant frequency in spleen and bone marrow, and red blood cell 
micronucleus frequency) and global gene expression changes were measured. All of the 
genotoxicity measures increased in a dose-dependent manner in both tissues. Gene expression 
analysis showed that DBC activates p53 signalling pathways related to cellular growth and 
proliferation, which was evident even at the low dose. Strikingly, the expression profiles of DBC 
exposed mouse spleens were highly inversely correlated with the expression profiles of the only 
published toxicogenomics dataset of enlarged mouse spleen. This analysis suggested a central 
role for Bnip3l, a pro-apoptotic protein involved in negative regulation of erythroid maturation. 
RT-PCR confirmed expression changes in several genes related to apoptosis, iron metabolism, 
and aryl hydrocarbon receptor signalling that are regulated in the opposite direction during 
spleen atrophy versus benzo[a]pyrene-mediated splenomegaly. In addition, benchmark dose 
modeling of toxicogenomics data yielded toxicity estimates that are very close to traditional 
toxicity endpoints. This work illustrates the power of toxicogenomics to reveal rich mechanistic 
information of immunotoxic compounds and its ability to provide information that is 
quantitatively similar to that derived from standard toxicity methods in health risk assessment. 
Key Words: human health risk assessment, mode of action, benchmark dose modeling, 
spleen.   

INTRODUCTION 
Polycyclic aromatic hydrocarbons (PAHs) are present as mixtures in many complex matrices, 
including petroleum, industrial emissions, cigarette smoke, smoked foods, municipal waste 
waters and airborne emissions from the internal combustion engines and waste incinerators 
(reviewed in  	

	). Dibenzo[def,p]chrysene (DBC; formerly known as 
dibenzo[a,l]pyrene) is the most carcinogenic PAH 	

. It has been suggested 
that its higher carcinogenic potency arises due to the higher reactivity of its diol epoxide 
metabolites towards DNA compared to the metabolites of other PAHs, resulting in a greater 
extent of DNA damage (reviewed in 	


 !"	

]). In addition, due to molecular geometry 
(steric hindrance), the ultimate carcinogenic metabolite of DBC (Fig. 1) preferentially forms 
DNA adducts at the N6 rather than N2 position of deoxyadenosine; N6 adducts are more resistant 
to nucleotide excision repair than N2 adducts that are formed by other PAHs (reviewed by 
[Harper et al., 2015]). In mice, DBC exposure leads to tumor formation at multiple sites, 
including lymphomas of the spleen (reviewed in [IARC, 2010]). DBC is considered “possibly 
carcinogenic” in humans (group 2B) by the International Agency for Research on Cancer 
(IARC) #$%  &'   !"   %  ( 	
)
. DBC 
concentration can reach 0.51-1.51 ng/m3 in ambient air particles, which is comparable to other 
PAHs such as benzo[a]pyrene (BaP) *%)+,-. We were unable to find any regulatory 
guidelines for DBC. 
In addition to the renowned carcinogenic activity, multiple studies have documented the 
immunotoxicity of PAHs (reviewed in %   	

], for example). The 
immunosuppressive properties of PAHs have been investigated using several assays, including 

primary antibody response to sheep red blood cells (also known as the “plaque-forming cell 
assay” (e.g., &	

.) and measurement of spleen weight (e.g., */)+++). The 
latter endpoint is measured using an Organisation for Economic Cooperation and Development 
(OECD) guideline (TG407) 0!* 	

,. The spleen has a highly organized lymphoid 
compartment and is involved in the removal of blood-borne microorganisms and cellular debris, 
in the phagocytosis of erythrocytes, and in iron recycling, and is considered the most important 
organ for antibacterial and antifungal immune reactivity 12  3 	

.. Therefore, 
spleen size is considered an effective measure of immune response since the spleen plays a 
primary role in initiating immune responses to blood-borne antigens (reviewed in 	

4). 
Previous work has shown that exposure of mice to PAHs leads to both spleen atrophy and 
splenomegaly, depending on the PAH and the route of exposure. For example, B6C3F1 female 
mice showed marked reduction in spleen weight and spleen cellularity after a 5-day exposure to 
50 and 100 mg/kg-bw per day BaP by intraperitoneal injection (5)++.. Similar 
reductions in spleen weight were reported in adult female C57BL/6N mice gavaged with 50 and 
150 mg/kg-bw per day of 7,12-dimethylbenz[a]anthracene (DMBA) for 5 days &	

.. 
In contrast, splenomegaly was observed in female NZB/WF1 mice that received BaP via dermal 
exposure for 30 days at 20 mg/kg-bw per day 	

.. 
Although the exact mechanisms underlying the splenic effects of PAHs remain to be 
elucidated, several molecules have been implicated as mediators of DBC- and DMBA-associated 
immunotoxicity (reviewed in &   	
)). In particular, spleen atrophy is p53-
dependent, as no effect on the spleen weight was observed in p53-deficient C57BL/6N female 
mice exposed to 17, 50, or 150 mg/kg-bw per day DMBA for 5 days, but not in wild-type 
exposed mice &   	

,. DMBA mediates p53 activation by p53 phosphorylation and 

nuclear accumulation in the murine spleen, which does not happen in mice lacking cytochrome 
450 1B1 (Cyp1b1) and microsomal epoxide hydrolase (mEH) &   	

,. It was thus 
proposed that p53-mediated apoptosis is responsible for DMBA cytotoxicity in the spleen at high 
doses &	

,, while at lower doses p53-mediated cell cycle arrest may also contribute 
to dose-dependent decreases in spleen weight (Scott Burchiel, personal communications).  
Similarly, DBC exposure is immunotoxic as measured by the plaque-forming cell assay and 
leads to p53 accumulation in the nucleus of spleen cells isolated from C57BL/6J mice in vitro (Li 
et al., 2010). In addition, DBC is bioactivated by CYP1B1 and mEH enzymes (Fig. 1; reviewed 
in &   	
)) to form immunotoxic reactive intermediates (5  67
3 	

). Interestingly, the aryl hydrocarbon receptor (AHR), which mediates PAH-
inducible expression of phase I and II metabolism genes including CYP1B1, appears to be 
dispensable for DMBA-mediated immunotoxicity in mouse spleen &	

,. Therefore, it 
is currently hypothesized that low, constitutive levels of CYP1B1 are sufficient for DMBA 
bioactivation in the spleen &	
). 
The objectives of this project were two-fold: i) to investigate the mechanisms involved in 
PAH-induced immunotoxic effects in mouse spleen using toxicogenomic tools; and ii) use this 
mechanistic information to compare toxicogenomics and traditional toxicity (apical) data in 
order to investigate the potential utility of toxicogenomics in human health risk assessment of 
immunotoxic compounds. 
MATERIALS AND METHODS 
Animal treatments. Adult male Muta™Mouse (strain 40.6; a transgenic mouse harboring 
bacteriophage lambda shuttle vector and frequently used in mutation research, described 

elsewhere &   )+,+, 9 weeks of age) were individually housed in a microVENT 
ventilated rack (Allentown Inc., Allentown, NJ) on a 12 h light/12 h dark cycle. Mice were bred, 
maintained, and treated in accordance with the Canadian Council for Animal Care Guidelines 
and all mouse work was approved by Health Canada’s Animal Care Committee. Mice received 
standard rodent chow (2014 Teklad Global standard rodent diet) and water ad libitum for the 
duration of the study. Mice were administered DBC (CAS no. 191-30-0, purity ≥ 98%, 
Cambridge Isotopes, Tewksbury, MA) dissolved in highly refined olive oil (Sigma-Aldrich, 
Oakville, ON, Canada) at 0.005 ml/g body weight. The doses (2.0, 6.3, and 20.0 mg/kg-bw per 
day) were administered by oral gavage for three consecutive days. Doses were selected based on 
preliminary dose range-finding work that showed a significant reduction in body weight 
exceeding 10%, paleness in the liver, as well as bone marrow cytotoxicity at doses above 5 
mg/kg-bw per day (administered daily for 28 days). Significant spleen reduction was observed in 
animals treated for 3 consecutive days with doses above 25 mg/kg-bw per day. There were 15 
animals in each dose group (5 harvested per each of 3 time points [i.e., 4, 24, and 72 h after the 
last exposure]), as well as in the vehicle control groups. Five mice from each dose group (and 
control group) were anesthetized using isoflurane gas and then euthanized via cervical 
dislocation followed by chest cavity opening 4, 24, or 72 h after the final dose. For the 72-h dose 
group, peripheral blood was collected from the facial vein 48 h after the last dose for 
micronucleus analysis following OECD guideline # 474 (OECD, 1997). For all time points, the 
spleen was removed, flash-frozen in liquid nitrogen, and stored at -80°C. To provide mechanistic 
insights into the “opposite” phenotype, splenomegaly, we used spleens from male mice of the 
same strain that were dosed with 0 or 100 mg BaP/kg-bw per day for 28 days (as described in 
Malik et al., 2012) and sacrificed 88 days after the last treatment.  

Genomic DNA isolation for mutation and DNA adduct analyses. Frozen spleen samples 
were minced and combined with 5-ml ice cold lysis buffer (1 mM Na2EDTA, 100 mM NaCl, 20 
mM Tris-HCl, pH 7.4), supplemented with 1% SDS (w/v) and 0.1 mg/ml RNase A, and 
incubated at 37˚C overnight with gentle shaking. Genomic DNA was then isolated using a 
phenol/chloroform extraction procedure described previously (Douglas et al., 1994; Vijg and 
Douglas 1996). Isolated DNA was dissolved in 100 µl TE buffer (10 mM Tris pH 7.6, 1 mM 
EDTA) and stored at 4˚C until use. 
DNA adduct analysis. The nuclease P1 digestion enrichment version of the 32P-postlabelling 
assay was used to measure DNA adduct frequency. The procedure was performed as described 
	
) '$	

-5	
)	.  
Mutant frequency analysis. The PGal (phenyl-β-D-galactoside) positive selection assay was 
used to assess the lacZ mutant frequency in DNA samples isolated from spleen from the 72-h 
post-exposure group only, as previously described (Lambert et al., 2005; Vijg & Douglas, 1996; 
Lemieux et al., 2011). Mutant frequency was calculated as the ratio of mutant plaque forming 
units (i.e., pfu) to total pfu, and analysis of mutant frequency data was performed as described 
previously (Lemieux et al., 2011). 
Peripheral blood micronucleus analysis. As indicated above, ~60-100 µl of blood was 
collected from the facial vein from the 72-h post-exposure group, 48 h after the last exposure, 
according to OECD guideline #474 (OECD, 1997). Blood samples were processed and fixed 
according to MicroFlow kit instructions (Litron Laboratories, Rochester, NY). Coded samples 
were shipped to Litron Laboratories for analysis of micronucleus (MN) frequency in 
reticulocytes (RETs) and normochromatic erythrocytes (NCEs). Samples were analyzed and 

stained according to (Dertinger et al., 2004). Frequencies of MN-RET, MN-NCE, as well as % 
RET were determined for all dose groups, with the exception of the high dose where the % RET 
was too low to score MN-RET frequency.  
Dihydro-8-oxo-2’-deoxyguanosine (8-oxo-dG) analysis. DNA was extracted by the DNAzol 
method as it produces minimal amounts of artificial DNA oxidation (Mangal et al., 2009), as 
described elsewhere '"	
).. Approximately 15 mg of spleen was used (N=5, 4- 
and 24-h post-exposure samples). Extracted DNA pellets were dissolved in 21 µL of Chelex 100 
resin-treated 50 mM dibasic sodium phosphate buffer (pH 7.4) containing 50 mM MgCl2 and 1 
mM desferal and digested with 1 unit of DNase I (type II, from bovine pancreas, Sigma-Aldrich, 
ON, Canada) for 1.5 h at 37°C. The pH was adjusted to 8.6 with 5 mM sodium phosphate dibasic 
buffer and the mixture was digested with 0.025 units of Phosphodiesterase I (type II from 
Crotalus adamaneus venom, Sigma-Aldrich) for 1.5 h at 37°C. Finally, the mixture was digested 
with 0.4 units of alkaline phosphatase (type III from Escherichia coli, Sigma-Aldrich) for 1.5 h. 
Methanol was added to the digest to a final concentration of 6%. The digest was stored at ‒80°C 
until HPLC analysis. A Waters 2690 Alliance HPLC system with a glassy carbon 
electrochemical detector and YMC-BASIC column were used for the analysis. Fifty millimolar 
phosphate buffer (pH 6.2) containing 6% methanol and 2 mM KCl served as the mobile phase. 
The voltage for 8-oxo-dG detection was +0.5 V and +0.9 V for 2’-deoxyguanosine detection; the 
flow rate was 1 mL/min. Results are expressed as 8-oxo-dG/2’-deoxyguanosine ratio. 
Immunoblot analysis. Approximately 50 mg of spleen from control and high dose samples 
collected 4 h and 24 h post-exposure was lysed by shaking with a metal bead for 10 min at 25 Hz 
in 1 mL of isotonic buffer (25 mM HEPES, 5 mM MgCl2, 1 mM EGTA, pH 7.5). Equal amounts 
of protein (20-30 mg, determined by BCA assay (Pierce Biotechnology, Rockford, IL, USA)) 

were loaded per lane on 4–15% Mini-PROTEAN® TGX™ pre-cast gels (Bio-Rad Mississauga, 
ON) and run for 1 h at 120 V. Protein was transferred onto Immobilon-P PVDF membrane 
(Millipore, Billerica, MA, USA) at 120 V for 1 h, blocked with 5% non-fat dry milk in 
phosphate buffered saline containing 0.1% Tween 20 for 1 h and probed with rabbit monoclonal 
BNIP3L antibody (Abcam, Cambridge, MA, USA, cat.no. EPR4033, 1:1000 dilution) or beta-
actin antibody (Cell signalling, Danvers, MA, USA, cat. no. 4970, 1:5000 dilution) for 1 h. 
Signal was visualized by probing with horse radish peroxidase-conjugated goat-anti rabbit 
polyclonal antibody (Assay designs, Ann Arbor, MI, USA, cat. no. SAB-300), 
chemiluminescence substrate (Millipore), and scanning with ChemiDoc XRS+ (Bio-Rad). 
Images were analyzed using AlphaEaseFC software version 3.1.2 (Alpha Innotech/Cell 
Biosciences, Santa Clara, CA). Results are expressed as relative band density compared to 
control, normalized to beta-actin expression. 
Total RNA isolation, microarray hybridization, and gene expression analysis. RNA was 
isolated, hybridized, and analyzed as described elsewhere 1	
)/	
). 
Samples with RNA integrity numbers above 6.0 (Agilent Bioanalyzer, Agilent Technologies, 
Mississauga, ON, Canada) were hybridized to Agilent 8x60 K whole genome microarrays. 
Agilent Feature Extraction Software (version 11) was employed for data extraction and the 
complete dataset has been deposited in the Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo/, accession number GSE72334). Normalization using locally 
weighted scatterplot smoothing (LOWESS) 8   	

	 in R %7*"'779
	
)
, determination of differential gene expression by microarray analysis of variance 
(MAANOVA) 	

, and calculation of false-discovery rate- (FDR) adjusted p-values 
were carried out as described elsewhere /	
). 

Real-time quantitative reverse transcription polymerase chain reaction (RT-PCR). A 
custom RT-PCR array, containing proprietary probes (Qiagen) was designed to validate 
microarray results. PCR arrays were run on a CFX96 real-time detection system (Bio-Rad). Ct 
values were normalized to Gapdh and gene expression was analyzed on-line at: 
http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php. 
Ion Proton™ Sequencing (RNA-Seq). Next-generation sequencing of eight spleen samples 
(control vs. high dose, 4 h after the last treatment, N=4) and 14 bone marrow samples (N=4 for 
control, low, and medium dose, and N=2 for high dose, 24 h post-treatment) was carried out 
using an Ion Proton™ sequencer (Life Technologies. Carlsbad, CA). Only one dose and time 
point was profiled for the spleen in order to confirm microarray results, while for the bone 
marrow, three doses were processed as no other toxicogenomics data were generated for this 
tissue. Poly-A RNA enrichment (DynaBeads® mRNA DIRECT Micro Kit) was performed for 
each spleen sample on 2.5 µg of total RNA. Ribosomal RNA removal (RiboMinus™ Eukaryote 
System v2) was performed for each bone marrow sample on 2.5 µg of total RNA. The Ion Total 
RNA-Seq Kit and AB Library Builder™ (option 1; whole transcriptome (Ion Total Library 
Version 1.0)) were used to fragment and prepare the sample libraries from poly-A enriched 
samples. The 3’-end barcode adapters provided in the Ion Xpress™ RNA-Seq Barcode 1–16 Kit 
Automated Library Construction kit were ligated to the ends of the fragmented libraries (each 
PCR product receiving its own unique barcode). Libraries were then amplified using the 
Platinum® PCR SuperMix High Fidelity. Each amplified library was quantified/qualified using 
the Agilent® High Sensitivity DNA Kit and Agilent® Bioanalyzer® 2100 Instrument. Aliquots 
of each library were pooled together for a total final concentration of 16 pM. Emulsion PCR 
(em-PCR) of the pooled libraries was done using Ion Sphere™ particles on the Ion OneTouch™ 

2 system. The Ion OneTouch™ ES was used to enrich for particles containing em-PCR products 
and the Qubit® 2.0 Fluorometer was used to assess the quality of enrichment. Enriched particles 
were deposited into the wells of an Ion P1™ chip (version 1) and sequenced by semi-conductor 
sequencing.  
The Proton™ Torrent Server version 4.0.2 interpreted the sequencing data and generated 
FASTQ files for each barcoded sample. Reads were trimmed to remove low quality read prefixes 
and suffixes, then aligned to the reference genome (GRCm38) using Star *2	
) and 
Bowtie :5;2	
)	. Following alignment, gene counting was performed with 
HT-Seq count (http://www-huber.embl.de/users/anders/HTSeq/doc/count.html) with the m 
parameter set to “intersection-nonempty” using the Ensembl GTF annotation (GRCm38v72). 
The table of counts was then imported into R where genes with a total count less than one read 
per million reads were removed from further analyses. The EdgeR %2	
)
 package 
was used for the analysis by normalizing with TMM %20	
)
 and calculating 
differentially expressed genes using the exactTest function. The data is publically available from 
Sequence Read Archive (SRA, http://www.ncbi.nlm.nih.gov/ SRA submissions: SRP062701 
(spleen) and SRP062765 (bone marrow)).  
Bionformatic analyses. All genes with the FDR P ≤ 0.05 and fold change ≥ 1.5 were 
uploaded into Ingenuity Pathway Analysis™ (IPA™, Ingenuity Systems, Redwood City, CA, 
USA) and NextBio™ (http://nextbio.com) to identify biological pathways, functions, or 
processes that are affected in the spleen by DBC exposure. IPA employs Fisher's exact tests to 
examine the significance of the association between a given dataset and the canonical pathways 
and functions as defined by IPA™. NextBio™ compares the input dataset to curated datasets to 
identify published cases of mouse models with similar gene profiles in the spleen. The meta-

analysis function was used to gain further insight into DBC-mediated immunotoxicity. The 
significance of negative or positive correlations between the query and curated datasets is 
assessed in NextBio™, taking into account a number of factors, most notably, directionality and 
strength of the overlap/enrichment between the two datasets 3'	
)
. 
Benchmark dose (BMD) modeling. Gene expression and apical data were analyzed using 
BMDExpress 8	

-, as we described previously 1	
).. The probes were 
fitted to each of the Hill, Power, Linear and Polynomial 2° models, with the following 
parameters: maximum iterations of 250, BMR factor of 1.349, confidence level of 0.95 and 
power restricted to ≥ 1. A best-fit model was selected based on: 1) the nested chi-square test cut-
off p-value of 0.05 to select between Linear and Polynomial models; 2) the lowest Akaike 
Information Criterion (AIC) to select between Hill and Power models; and 3) the goodness-of-fit 
p-value for likelihood ratio test of > 0.05. In the case that the k parameter was less than 1/3 of the 
lowest positive dose, the Hill model is flagged, and the next best fit model was selected if it had 
a goodness-of-fit p-value > 0.05. In addition, BMD values were generated for the IPA canonical 
pathways and for the “Cellular growth and proliferation, hematological system development and 
function, hematopoiesis top diseases & function” IPA network since it was the only network that 
could be described by the genes that were affected by DBC at all doses and all time points (seven 
and ten genes for 4- and 24-h time points, respectively. In addition, BMDs were derived for the 
gene Cdkn1ausing both DNA microarray (derived in BMDExpress) and RT-PCR because of its 
established association with DNA damage response :   	
).. The individual gene 
expression (delta Ct values from RT-PCR) data for Cdk1na were analyzed as described 
elsewhere '"	
).. Briefly, the US EPA’s BMDS software version 2.50, with the 
patched continuous polynomial model and Wizard Output Report (described at: 

http://www.epa.gov/ ncea/bmds/), was used. Gene expression (delta Ct) values were fit against 
five continuous (linear, polynomial, power, Hill, and exponential) dose-response models and the 
best model was selected based on the lowest Akaike’s information criterion, provided that chi-
square goodness of fit p-value was > 0.1. The default BMDS 2.50 settings were used to obtain 
the BMD1SD and their lower 95% confidence limit (BMDL1SD) values. 
Statistical analyses for lacZ, MN, and DNA adducts. The lacZ, MN, and DNA adduct data 
were analyzed using SAS software, Version 9.1 of the SAS System for Windows (© 2002-2010 
by SAS Institute Inc, Cary, NC) by Poisson regression. The data were fit to the model log(E(Yi)) 
= log ti + βxi, where E(Yi) is the expected value for the ith observation, β is the vector of 
regressions coefficients, xi is a vector of covariates for the ith observation, and ti is the offset 
variable used to account for differences in observation count period (i.e., pfu). The offset (i.e., 
natural log of pfu) was given a constant coefficient of 1.0 for each observation, and log-linear 
relationships between mutant count and test article concentration were specified by a natural log 
link function. Type 1, or sequential analysis, was employed to examine the statistical 
significance of the chemical treatment. 
Other statistical analyses. Spleen and liver weights were analyzed by one–way ANOVA  in 
Microsoft Excel. The liver somatic index, spleen somatic index, and 8-oxodG data were analyzed 
in R. An ANOVA was conducted to determine whether there was a treatment effect, and post-
hoc comparisons of each dose with control samples were then employed using the Tukey honest 
significant difference test. Scrutiny of the residuals revealed that all data met the assumptions of 
homogeneity of variance and normality; therefore, no data transformations were required. 
Immunoblotting results (band densitometry values converted to fold-change in the high dose 
over control) for Bnip3l were analyzed using the unpaired t-test function in Microsoft Excel. 

RESULTS 
General and organ-specific response of Muta™Mouse to DBC 
Mice exposed to three consecutive doses of 2.0, 6.3, or 20.0 mg/kg-bw per day DBC 
displayed no overt signs of toxicity as assessed by standard serum chemistry screens; the only 
significant effects noted were a ~2-fold reduction in serum triglycerides at the medium dose, and 
a ~25% decrease in serum blood urea nitrogen 4 and 24 h after the last treatment, respectively 
(data not shown). There was no overall weight loss compared to the control group. However, the 
mice displayed profound loss of spleen weight (i.e., somatic index or % body weight) that was 
greatest at the high dose 72 h post-treatment (over 40% loss, Fig. 2). No changes were observed 
in the weight of the livers (Supplementary Fig. 1) or any other organs (data not shown).  
DNA adducts as indicators of DBC metabolism and tissue exposure 
DNA adducts were measured in the spleen and bone marrow by 32P-postlabeling analysis. 
There was a dose-dependent increase in the levels of DBC-DNA adducts across all 
concentrations and time points in both spleen and bone marrow (Fig. 3). The main adducts were 
derivatives of the DBC metabolite DBC-11,12-diol-13,14-epoxide    	
) and 
representative autoradiograms of the obtained DNA adduct profiles are shown in Supplementary 
Fig. 2. No adducts were detectable in DNA isolated from control (untreated) animals. The spleen 
had roughly 2-fold higher levels of adducts than the bone marrow. There was a clear decrease in 
the adduct levels from 4 to 72 h in the bone marrow that was most pronounced at the high dose 
(Fig. 3B); on the contrary, there was over a two-fold increase in adduct levels at the highest dose 
from 4 to 24 h in the spleen (Fig. 3A). 

LacZ mutant frequencies in spleen and bone marrow 
Mutant frequency for the lacZ transgene was evaluated in the spleen and bone marrow 72 h 
after the last exposure (Fig. 4). Despite 2-fold higher adduct levels in the spleen (Fig. 3), bone 
marrow had much higher mutant frequencies, reaching over 10-fold increases above controls for 
the high dose (Fig. 4). In contrast to the bone marrow, a consistent dose-response for induced 
mutant frequency in the spleen was not observed. 
Circulating reticulocytes and micronucleus formation 
Micronucleus formation was measured in peripheral blood collected 46 h after the last 
exposure by flow cytometry * 	

. The approach exploits cell-surface markers 
that enable the analysis of newly-formed erythrocytes (i.e., RETs) that are less than 48-h old and 
mature erythrocytes (i.e., NCEs). There were statistically-significant increases in the formation 
of both MN-RETs and MN-NCEs (Fig. 5). There was clear dose-response effect for the increase 
in both MN-NCEs and MN-RETs, but the latter was more pronounced, giving rise to a much 
steeper slope in the dose-response curve. At the highest dose, the % RET was < 0.03% (Fig. 5B), 
which is too low to reliably score MN-RET frequency. 
DNA oxidation 
DNA oxidation in the spleen was quantified using a modified HPLC method that measures an 
established DNA oxidation marker, dihydro-8-oxo-2’-deoxyguanosine (8-oxo-dG) '" 
 	
).. In contrast to the other genotoxicity endpoints (i.e., DNA adducts, lacZ mutant 
frequency, and micronucleus formation), 8-oxo-dG levels increased only at the highest dose and 
only at the 4 h post-exposure time-point (1.9-fold increase vs. control, Fig. 6). 

Gene expression changes in the spleen detected by Agilent microarrays 
DBC affected the expression of 45, 361, and 1566 probes at the low, medium, and high doses 
respectively, 4 h after the last treatment, and 195, 595, and 1204 probes, 24 h after the last 
treatment (Supplementary Table 1). Hierarchical cluster analysis of all of the differentially 
expressed genes revealed a clear separation between control and treatment groups 
(Supplementary Fig. 3). The highest dose was on a separate branch from all other treatments, 
regardless of time point. Thus, gene expression profiles were primarily affected by dose and 
demonstrate clear treatment effects as a result of DBC exposure. The complete microarray data 
set for this study is available through the Gene Expression Omnibus at NCBI 
(http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE72334. 
Eighteen genes were perturbed at all doses and both time points (Table 1). Analysis of these 
genes in IPA revealed that 11 out of these 18 genes belong to a “cellular growth and 
proliferation, hematological system development & function, hematopoiesis” network. The 11 
genes are: B-cell lymphoma (Bcl2)/adenovirus E1B 19kDa interacting protein 3-like (Bnip3l), 
cyclin-D1-binding protein 1 (Ccndbp1), ephrin type-B receptor 6 (Ephb6), FCH and double SH3 
domains protein 1 (Fchsd1), fibroblast growth factor 13 (Fgf13), methyl-CpG binding domain 
protein 5 (Mbd5), nuclear receptor coactivator 4 (Ncoa4), serine/threonine-protein phosphatase 
PP1-beta catalytic subunit (Ppp1cb), Sry (sex determining region y)-box 13 (Sox13), stefin A3 
(Stfa3), and Yip1 domain family, member 4 (Yipf4). Activation of “cell cycle: G2/M DNA 
damage checkpoint regulation” and inhibition of “cyclins and cell cycle regulation” networks 
occurred 4 or both 4 and 24 h post-exposure to the high dose, respectively (Table 2), in parallel 
with reduced gene expression of cyclins A, B, D1, and E. Cdkn1a was upregulated by DBC at all 
doses 4, but not 24 h after the last exposure, consistent with its predicted activation based on the 

gene expression of its downstream targets at the medium dose at 4 h, and the medium and high 
doses 24 hrs post- exposure (Supplementary Table 2).  
In addition to p53-mediated cell cycle arrest, DBC exposure affected the expression of genes 
involved in two other p53 functions: apoptosis (upregulation of Bcl-2-binding component 3 
(Bbc3, also known as p53 upregulated modulator of apoptosis or PUMA)) and antiapoptosis 
(downregulation of baculoviral IAP repeat containing 5 (Birc5), cyclin B2 (Ccnb2), and protein 
regulator of cytokinesis 1 (Prc1)). Bbc3 was upregulated 24 h post-exposure to the highest dose, 
whereas Birc5, Ccnb2, and Prc1 were downregulated 4 h post-exposure to the highest dose 
(Supplementary Table 1). Ccnb2 and Prc1 were also downregulated 24 h post-exposure to the 
medium and high doses. In addition to p53, the IPA “upstream activators” application predicted 
that a number of other transcriptional regulators were affected by DBC in the spleen, including 
activation of Bnip3l, and inhibition of erythropoietin (Epo) and erythroid transcription factor or 
GATA-binding factor 1 (Gata-1) (Supplementary Table 2).  
Query against curated datasets in NextBio revealed that DBC-induced spleen profiles were 
strongly negatively correlated with spleen expression profiles from Bnip3l knock-out mice 
*<	

-. Specifically, 634 genes that were upregulated in the spleens of MutaTMMouse 
exposed to the high dose of DBC were downregulated in the spleens of mice lacking Bnip3l and, 
conversely, 884 genes that were downregulated in response to DBC were upregulated in the 
spleens of Bnip3l knock-out mice (Fig. 7). Strikingly, Bnip3l gene expression was significantly 
downregulated relative to control at all three doses and time points in our study (Table 1). The 
Bnip3l-deficient mice exhibit the opposite phenotype to spleen atrophy that we report here, i.e., 
massive splenomegaly, characterized by erythroblast hyperplasia and reduced apoptosis during 
erythrocyte maturation in the bone marrow and spleen *<   	

-. The two opposite 

phenotypes are consistent with the opposite pattern of gene expression (negative correlation) 
between this study and the aforementioned *< 	

- study. Bnip3l is a pro-apoptotic 
protein that regulates the production of erythrocytes, maintains hematological homeostasis, and 
affects spleen size *<	

-. 
Overview of altered gene expression in the spleen detected by RNA-Seq 
RNA-Seq revealed 2465 differentially expressed transcripts at the highest dose 4 h after the 
last treatment (Supplementary Table 3). Of these, 497 genes were also identified as differentially 
expressed by the Agilent microarrays. Analysis in IPA revealed that shared probes had disease 
functions and canonical pathways related to cell cycle, DNA damage, and hematological disease. 
Both technologies identified “cell cycle”, “cellular growth and proliferation”, and “cell death and 
survival” as top molecular and cellular functions perturbed by DBC (Supplementary Fig. 4). 
Similar to the microarray data, RNA-Seq analysis suggested activation of p53, Cdkn1a, and 
Bnip3l, and inhibition of Epo and Gata-1. 
Validation of gene expression by RT-PCR 
Ten genes were selected for validation of microarray results by RT-PCR. The selection was 
based on the involvement of the genes in the pathways described above. The selected genes were 
involved in p53-mediated DNA damage response (Bbc3, Birc5, Cdkn1a, and Prc1), heme 
metabolism (ferrochelatase (Fech), heme oxygenase (decycling) 1 (Hmox1), and AHR-mediated 
signalling (Cyp1b1 and NAD(P)H dehydrogenase, quinone 1 (Nqo1)). In addition, the expression 
of mitochondrial fission regulator 1 (Mtfr1) and Bnip3l was examined by RT-PCR. Table 3 lists 
expression values obtained by Agilent microarrays for the 10 genes selected for the validation by 
RT-PCR. All of the ten genes except Cyp1b1 had expression changes > ±1.5-fold relative to 
controls and FDR-adjusted p-values < 0.05 on DNA microarrays. Cyp1b1 expression was just 

below a 1.5-fold change (i.e., 1.44 and 1.48-fold increase over control 4 and 24 h after the last 
treatment, respectively (Table 3)). Bnip3l and Fech had clear dose-dependent responses for both 
time points, as did Birc5 at the 24 h time point. 
RT-PCR confirmed the changes in the expression for nine out of 10 genes; alterations in 
Hmox1 levels observed using DNA microarrays (Table 3) were not reproduced by RT-PCR 
(Table 4). In addition, RT-PCR revealed that Cdkn1a was upregulated at all doses and time 
points. RNA-Seq confirmed expression changes following DBC exposure of all perturbed genes 
with the exception of the relatively low abundant Cyp1b1 transcript (Table 5). RNA-Seq also 
detected 2.1-fold upregulation of Hmox1. 
Confirmation of reduced Bnip3l expression by immunoblotting 
Bnip3l expression was analyzed by immunoblotting. Bnip3l may be visualized by 
immunoblotting as both a monomer and a dimer of approximately 42 and 80 kiloDaltons, 
respectively #;   )+++, which can also be seen in Fig. 8. The expression of Bnip3l 
dimers for both time points and the Bnip3l monomer for the 24 h time point were significantly 
reduced at the high dose of 20 mg/kg-bw per day, in agreement with gene expression profiling 
by microarrays, RT-PCR, and RNA-Seq (Table 5). 
Comparison of the expression of selected genes in the PAH-induced models of spleen atrophy 
versus enlargement 
As the pattern of gene expression associated with DBC-induced spleen atrophy was the 
opposite to what is seen in the spleen of Bnip3l knock-out mouse *<   	

-, we 
hypothesized that alteration of spleen size in response to PAH exposure in mice is controlled by 
a similar set of genes. To this end, we examined the expression of the RT-PCR-validated genes 

in the spleens of MutaTMMouse males that displayed approximately 5-fold increases in spleen 
weight 88 days after a 28-day exposure to BaP, from a separate experiment (Fig. 9A). Six out of 
10 genes were differentially expressed (±1.5-fold change versus control with FDR-adjusted p-
value < 0.05), out of which five genes showed the opposite pattern of altered expression in BaP 
versus DBC-treated mice (Fig. 9B). The five genes were Birc5, Prc1, Fech, Nqo1, and Cyp1b1. 
Overview of altered gene expression in the bone marrow detected by RNA-Seq 
Genomic responses were evaluated in bone marrow 24 h post-exposure by RNA-Seq. DBC 
exposure affected the expression of 4, 94, and 893 genes in the bone marrow (FRD p-value < 
0.05; fold change > ± 1.5) at low, medium, and high doses, respectively (Supplementary Table 
4). Table 6 provides a comparison between the bone marrow and spleen results for the 10 genes 
validated by microarrays, RNA-Seq, and RT-PCR. The most striking difference is the strong 
dose-response and large fold changes in Cdkn1a expression in the bone marrow, with 6.3-, 10.6-, 
and 22.8-fold increases over controls at the low, medium, and high doses, respectively (Table 6). 
Cdkn1a and another gene in the p53 signalling pathway, Ccnd1, were two out of only four genes 
perturbed by DBC at the lowest dose in the bone marrow (Supplementary Table 4).  
Consistent with this result, IPA identified p53 activation at medium and high doses in 
bone marrow RNA-seq profiles, with 13 and 69 differentially expressed genes that are known to 
be controlled by p53. Out of the 10 genes that were differentially expressed by microarrays, RT-
PCR, or both, six genes were also differentially expressed in the bone marrow, as measured by 
RNA-seq (Cdkn1a, Bbc3, Prc1, Mtfr1, Hmox1, and Cyp1b1) (Table 6). Direction of fold change 
(i.e, up- or down-regulation) was also consistent between the two tissues. Unlike in the spleen, 
Bnip3l was unaffected in the bone marrow. Overall, genomic responses to the high dose of DBC 
in the spleen and the bone marrow were very similar. For example, pathway analysis revealed 

that five out of the seven top canonical pathways with z-scores above 2.0 were similarly affected 
by DBC in spleen and bone marrow (Supplementary Fig. 5). In addition, the profiles supported 
the activation of p53 and Bnip3l in both tissues (Supplementary Table 5). 
Benchmark dose (BMD) analysis of toxicogenomics data 
In order to achieve our objective of investigating the utility of toxicogenomics for 
quantitative health risk assessment of immunotoxic compounds, BMD modeling was applied. 
Table 7 summarizes benchmark dose (BMD) values derived from microarray results. The BMD 
(BMDL) values ranged from 0.066 (0.025) mg/kg-bw per day for “Heparan sulfate biosynthesis” 
to 4.46 (2.78) mg/kg-bw per day for the “Cell cycle: G2/M DNA damage checkpoint regulation” 
pathway. Published literature and our data suggest that DBC exposure affects cell cycle-related 
pathways, which may be relevant to its immunotoxicity. In addition, AHR signalling is important 
in mediating many adverse effects associated with PAH exposure. That, along with the fact that 
“cell cycle: G2/M DNA damage checkpoint regulation”, “cyclins and cell cycle regulation” and 
“aryl hydrocarbon receptor signalling” were the only three IPA pathways that met the default z-
score cut-off of 2.0 (Table 2), led us to focus on these IPA pathways of potential relevance to 
health risk assessment of DBC. We also included the “cellular growth and proliferation, 
hematological system development & function, hematopoiesis” network containing 11 out of 18 
genes that were affected by DBC at all doses. It has previously been suggested that the most 
sensitive (i.e., with the lowest median BMD values from toxicogenomic data) pathway that 
contains at least five genes be considered for quantitative risk assessment (e.g., point of 
departure selection), regardless of its biological significance 9	
)). Thus, we also 
present the BMD values for the IPA pathway with the lowest BMDLs at the 10th percentile of all 
affected genes in the network. At 4 h and 24 h, these are “Calcium signaling” and “Heparan 

sulfate biosynthesis” with BMD (BMDL) values of 2.2 (0.25) and 0.066 (0.025) mg/kg-bw per 
day, respectively. In addition, modeling the expression of Cdkn1a, a proposed marker of DNA 
damage response :	
)., yielded BMD and BMDL values of 1.7 and 1.2 mg/kg-bw per 
day, respectively, 4 h post-exposure, using microarray data. Similarly, BMD modeling of RT-
PCR data gave BMD and BMDL values of 0.70 and 0.22 mg/kg-bw per day, respectively, 4 h 
post-exposure. These values are within the range of the pathway BMDs presented in Table 7. 
Comparison of toxicogenomic and apical data 
Finally, to compare toxicogenomics and traditional toxicity (apical) data, BMD values of 
potential use in health risk assessment that would be derived from our toxicogenomics and apical 
(spleen weight) data were compared. The lowest BMDL for toxicogenomic data was for the 
heparan sulfate biosynthesis pathway (HSBP). In addition to having the lowest BMDL across all 
pathways, HSBP contained eight genes that could be modelled and had a BMD/BMDL ratio of 
2.6 (see Supplementary File 1), indicative of an acceptable fit for the BMD modeling 1
 	
).. The BMDL for this pathway was 0.025 mg/kg-bw per day. Interestingly, heparan 
sulfate controls fibroblast growth factor signalling and thus plays a role in controlling stem and 
progenitor cell fate (reviewed in   2 	

4-), which is in agreement with our 
finding that cell cycle-related processes are important for DBC-mediated spleen atrophy. The 
BMDL values for HSBP and spleen weight (0.025 and 0.095 mg/kg-bw per day, respectively) 
differed by 3.8. Similarly, the BMDL value for “cellular growth and proliferation, hematological 
system development & function, hematopoiesis” was 0.080 mg/kg-bw per day, also very much 
in-line with our apical BMDL. 

DISCUSSION 
DBC is the most potent carcinogenic PAH studied to date, based on a much higher number of 
tumors observed in SENCAR female mice in an initiation-promotion study (2
)++ and a much larger response in a forward in vitro mutation assay *)++4 relative 
to other PAHs. The present study delves into the immunotoxic effects of DBC, manifested as 
spleen atrophy in exposed mice, and demonstrates that DBC is genotoxic to both spleen and bone 
marrow cells. Transcriptional profiling under conditions of induced spleen atrophy and 
enlargement that take place in mice in response to DBC exposure confirms the importance of 
p53 signalling, Cyp1b1 expression, and cell cycle-related pathways. Moreover, the analyses 
suggest that Bnip3l is one of the principal mediators of DBC-induced spleen atrophy. This 
toxicogenomics study also provides other mechanistic insight into DBC-mediated 
immunotoxicity. Importantly, the work supports that BMD values produced from pathway 
analysis are in concordance with apical data. The results generate additional hypotheses, such as 
the potential involvement of the heparan biosynthesis pathway that is known to regulate growth 
factor-mediated determination of stem and progenitor cell fate, in the immune-related effects of 
PAHs. Overall, the pathway perturbations identified in response to DBC are in excellent 
agreement with its known and emerging genotoxic mode of action, and provide sound 
explanations for DBC/PAH-mediated immunotoxicity.  
The genotoxic effects of DBC on bone marrow are more pronounced than on the spleen as 
judged by the higher lacZ mutant frequency (Fig. 4) and the significant decline in RETs. At the 
same time, DNA adducts were markedly lower in the bone marrow following DBC exposure, 
and significantly decreased from 24-h to 72-h (Fig. 3), presumably due to apoptotic removal of 
bone marrow cells. The observed differences in the frequency of adducts and mutations is 

determined by the dynamic interplay between a number of variables that can contribute to these 
differences, including rates of phase I and II metabolism, DNA damage response and DNA 
repair pathways, and cell turnover. Toxicogenomics data allow us to explore the reasons for 
potential differences in adduct and mutant frequencies in the two tissues. The most striking 
difference observed in our data was the strong dose-response and large fold changes in Cdkn1a 
expression in the bone marrow, with 6.3-, 10.6-, and 22.8-fold increases over controls at the low, 
medium, and high doses, respectively (Table 6). Cdkn1a and another gene in the p53 signalling 
pathway, Ccnd1, were two out of only four genes perturbed by DBC at the lowest dose in the 
bone marrow (Supplementary Table 4). Cdkn1a is upregulated by xenobiotics such as BaP (e.g., 
1   	
).) through p53 activation, and plays a role in DNA damage response by 
inducing cell cycle arrest, inhibition of DNA replication, and apoptosis (reviewed in ;;
 	
)
). Cdkn1a can induce cell cycle arrest by several mechanisms, including inhibition of 
the activity of cyclins involved in the G1, G2, and S-phases of the cell cycle (reviewed in 
;;	
)
). Therefore, greater Cdkn1a induction appears to reflect greater sensitivity 
of the bone marrow over the spleen to DBC exposure. 
The percent of MN-RETs in the peripheral blood supports the high degree of genotoxicity 
historically observed in the bone marrow =5*'((5	
); the 
high % MN-RET (Fig. 5) suggests that the bone marrow is a sensitive target of DBC-induced 
genetic toxicity in mice. Indeed, the % MN-RET was over 4.0 % for the medium dose, which is 
over 10-fold higher than the maximal range (0.05 – 0.3%) of basal MN-RET levels in most rat 
and mice strains (reviewed in *   	

) and is thus indicative of a very high 
genotoxic potency that is rarely achieved by chemical exposure (Dertinger, personal 
communications). In addition, the % MN-RET observed here at the medium dose of DBC (6.3 

mg/kg/day) was four times higher than the % MN-RET induced by a more than 10-fold higher 
(75 mg/kg/day) dose of BaP in our previous study over 28 days :>	
)). This very 
high % MN-RET frequency confirms the much higher mutagenic potency of DBC compared to 
other PAHs. Similarly, lacZ mutant frequency at the high dose of DBC was approximately 2-, 4-, 
and 8-fold higher in the bone marrow than in the glandular stomach, lung, and liver, respectively, 
in response to 28-day exposure to a similar dose of 25 mg BaP/kg-bw per day for 28 days 
:>   	
))1   	
)	:22   	
)	. These data further support strong 
mutagenic potency of DBC. 
In contrast to other genotoxicity endpoints measured here (i.e., DNA adducts, lacZ mutant 
frequency, and micronuclei formation), 8-oxo-dG levels were increased at the high dose 4 h post-
exposure (1.9-fold increase vs. control, Fig. 6) and not 24 h after the last exposure. The results 
indicate that DBC-mediated DNA oxidation is rapidly repaired in the spleen. This, along with the 
lack of clear induction of genes related to oxidative stress response, suggests that oxidative stress 
in the spleen is a secondary effect of DBC exposure and is not directly related to spleen atrophy. 
An interesting result in the present study is the central role of Bnip3l in the spleen following 
DBC exposure. Expression profiles of the spleens of mice exposed to DBC were negatively 
correlated with those of Bnip3l knock-out mice; these two mouse models also exhibit opposing 
effects on spleen size. Bnip3l is a pro-apoptotic protein that is involved in negative regulation of 
erythroid maturation. Splenomegaly reported in the Bnip3l-deficient mice is associated with 
erythroblast hyperplasia and reduced apoptosis during erythrocyte maturation *<	

-. 
It is thus conceivable that erythroid hyperplasia and apoptosis of erythroblasts can directly affect 
the spleen size (G. W. Dorn II, personal communication). Such a rapid effect on the spleen 
phenotype seen in response to DBC in our study is consistent with rapid turnover of certain 

splenocytes in the mouse, such as dendritic cells that have a half-life of 1.5-2.9 days 3
	


. Splenic Bnip3l was down-regulated by DBC at all doses. Therefore, p53-mediated cell 
cycle arrest and apoptosis of the splenocytes in MutaTMMouse, and the involvement of Bnip3l in 
response to DBC, offers a reasonable explanation for the observed spleen atrophy.  
The role of Bnip3l and p53-mediated effects on cell cycle and apoptosis in splenocytes in 
response to DBC, described here, is in accord with previous reports describing marked reduction 
in the number of spleen and bone marrow cells in response to PAHs. For example, a 5-day 
exposure of female B6C3F1 mice to BaP resulted in an approximate 2-fold reduction in spleen 
cellularity (nucleated cells) and bone marrow cellularity (CD45R+ cells) (  5
)++.. Decreased spleen cellularity following BaP exposure was attributed to the effects of BaP 
on B lymphocyte hematopoiesis in the bone marrow (5)++.. Similarly, BaP-
mediated splenomegaly in NZB/WF1 mice was characterized by decreased numbers of B (Ig-
positive) cells, in parallel with ~2-3-fold increases in the number of null cells (non-T, non-B 
cells) that are thought to be red blood cell precursors that expand during extramedullary 
hematopoiesis in the spleen    	

.. Extramedullary hematopoiesis is a 
compensatory response to hemolysis and may be induced if hematopoiesis in the bone marrow 
fails to keep up with the replacement needs to maintain adequate circulating levels of red blood 
cells (reviewed in 1   	
)). In addition, damaged erythrocytes are trapped in the 
mononuclear phagocytic system in the spleen, which also leads to splenomegaly (reviewed in 
 	

-). That DBC administration leads to hemolytic anemia is supported by the sharp 
decrease in reticulocytes observed at all doses (Fig. 5B).  
As described above, spleen weight is an important toxicological endpoint, related to the 
function of the immune system and thus is measured, according to the OECD guideline TG407 

0!* 	

,. However, an important limitation is that although we measured red blood cell 
count, our study lacked anchoring against other immune function endpoints, such as an 
assessment using the plaque-forming cell assay. In addition to spleen atrophy, several studies 
have reported increased spleen weights in laboratory animals in response to PAHs. For example, 
30-day exposure of female NZB/WF1 mice to comparable doses of BaP (20 and 40 mg/kg-bw 
per day) led to ~2-4 fold increases in the spleen weight (Booker and White, 2005). In addition, 
spleen atrophy followed by splenomegaly has been described in C3H/He mice exposed to single 
acute doses of cyclophosphamide 32   )+--. The response of the spleen to 
cyclophosphamide in C3H/He mice was characterized by bimodal response of splenocytes 
(nucleated and Ig-positive cells) consisting of an initial decline (days 0-3 post-exposure), 
followed by an increase (days 5-9), and a subsequent return to normal levels (days 9-13) 32
)+--. Therefore, we hypothesize that spleen atrophy and splenomegaly are the “two sides of 
the same coin”, i.e., we expect that splenomegaly is, at least in part, a compensatory response 
that arises after spleen atrophy due to increased apoptosis, cell cycle arrest, and hemolytic 
anemia. More specifically, we hypothesize that both initial atrophy followed by enlargement of 
the spleen in response to PAHs are mediated by a similar set of genes.  
In agreement with our hypotheses, RT-PCR analysis showed the opposite pattern of altered 
gene expression for five out of 10 genes examined under conditions of enlarged versus atrophied 
spleens (Fig. 9B). Genes exhibiting opposite expression patterns include the anti-apoptotic 
proteins Birc5 and Prc1, AHR-regulated Nqo1, CYP1B1, and Fech (the final enzyme in the 
heme biosynthesis pathway). With respect to AHR regulation of Nqo1 and CYP1B1, it is worth 
noting that cross talk between AHR and other transcription factors, such as nuclear factor-
erythroid 2 p45 subunit-related factor 2 (Nrf2), exists. Indeed, Nqo1 contains a functional 

antioxidant response element and is a subject of transcriptional control of Nrf2 (reviewed in 
1	
).). Down-regulation of the anti-apoptotic genes Birc5 and Prc1 following acute 
exposure to DBC, and up-regulation following subchronic exposure to BaP, is consistent with 
the notion that activation or inhibition apoptosis in splenocytes and/or their precursors is 
mechanistically linked to spleen atrophy and enlargement, respectively. Fech is transcriptionally 
up-regulated during low oxygen conditions, presumably to increase heme availability for 
enhanced erythropoiesis (reviewed in '"   	
))). Down-regulation of Fech 
during DBC-mediated spleen atrophy is consistent with increased iron availability due to 
hemolytic anemia. DBC also down-regulated many other genes involved in heme metabolism, 
including hemoglobin subunit beta-1, hemoglobin alpha, adult chains 1 and 2, erythropoietin 
receptor, aminolevulinic acid synthase 2, erythroid (Supplementary Table 1). Like Fech, many of 
these proteins are up-regulated by hypoxia to augment erythropoiesis (reviewed in '"
 	
))). Toxicogenomic profiling of MutaTMMouse spleen in response to acute 
administration of DBC suggests increased quantity of reticulocytes and megakaryocytes, 
inhibited maturation of erythroid cells, inhibited survival of red blood cells, and inhibited 
survival of erythroid progenitor cells (data not shown). This, in combination with the expression 
patterns of Fech, suggests that heme biosynthesis and hematopoiesis/erythropoiesis are inhibited 
during PAH-induced spleen atrophy and activated during PAH-induced splenomegaly in mice.  
Cyp1b1 was another gene that was altered during spleen atrophy (upregulated) and 
splenomegaly (downregulated). As described in the introduction, CYP1B1 appears to be 
important for the metabolic activation of DBC and its immunotoxicity. For example, spleen 
atrophy in C57BL/6N mice in response to DMBA is abrogated in Cyp1b1-/- animals &
	

.. In addition, Cyp1b1 knock-out (in mice) abolishes p53 activation by its phosphorylation 

and nuclear translocation in response to DMBA &	

,. It is worth noting that Cyp1b1 
is up-regulated over 160-fold compared to controls 4 h after the last exposure in the lungs of 
male C57BL/6J mice exposed to 150 mg BaP/kg-bw per day for three days, but then its 
expression rapidly declines 24 h post-treatment 1   	
)., presumably due to the 
completion of BaP metabolism. Given that 88 days after the last BaP administration in our study 
all of the BaP is expected to be fully metabolized and eliminated, these persistent changes in 
Cyp1b1 expression suggest that it may have other important role(s) in controlling spleen size 
and, potentially, erythropoiesis that extend beyond xenobiotic metabolism. An important 
distinction between DBC and BaP that has to be kept in mind while comparing and generalizing 
the immunotoxic effects of these two compounds is that BaP is metabolized to redox-cycling 
BaP quinone metabolites that can lead to immunotoxicity through oxidative stress-related 
pathways (reviewed in &   	
)). For DBC, on the other hand, oxidative stress 
appears to only have a minor contribution based on our gene expression data and DNA oxidation 
measurements. 
According to our hypothesis that altered spleen weight is due to perturbations in the same 
network of genes, Bnip3l down-regulation following DBC exposure appears to be an upstream 
event launched to augment erythropoiesis. As a result, at later time points following DBC 
exposure splenomegaly may take place, as seen in our case 88 days following 28-day BaP 
exposure (Fig. 9A). Prolonged downregulation of Bnip3l and, possibly, other pro-
apoptotic/tumor suppressor(s) lead(s) to a phenotype that is similar to one described in Bnip3l-
deficient mice *<	

-. That, in combination with increased steady-state levels of both 
normal and damaged erythrocytes stored in the spleen, and extramedullary hematopoiesis, 

appears as a reasonable mechanism behind increased spleen mass following sub-chronic 
exposure. 
Bnip3l and the other 10 genes that were perturbed by DBC at all doses are part of a “cellular 
growth and proliferation, hematological system development & function, hematopoiesis” IPA 
network. That this network is affected by DBC in association with spleen atrophy is not 
surprising, as the spleen is a major hematopoietic organ in mice. Thus, we argue that the 
mechanism of action of DBC on the spleen involves perturbations in this pathway leading to 
toxicity in bone marrow cells, spleen atrophy, and immunotoxicity. The BMDL for this network 
is 0.080 mg/kg-bw per day, which is comparable to the lowest BMDL for spleen weight (0.095 
mg/kg-bw per day) in our study. BMD modeling of the data generated by two different 
technologies, microarrays and RT-PCR, resulted in very similar BMD values (i.e., BMD(L)s of 
1.7(1.2) and 0.70(0.22) mg/kg-bw per day, respectively), using Cdkn1a. Increased expression of 
Cdkn1a supports initiation of a DNA damage response :  	
).. These BMD values are 
very close to those of the pathways relevant to the immunotoxic MOA of DBC. We previously 
proposed that toxicogenomics-derived BMDLs can be used in quantitative risk assessment when 
apical data are not available 1	
).'"	
).2. The current example with 
DBC further confirms this notion.  Similarly, BMDL values of 0.204 and 0.025 mg/kg-bw per 
day were found for AHR signalling and heparan sulfate biosynthesis pathways, respectively 
(Table 8); these BMDLs are also close to the apical BMDL for spleen weight (0.095 mg/kg-bw 
per day). Thus, our experiment supports the utility of quantitative toxicogenomics for risk 
assessment of immnotoxic chemicals that are also genotoxic.  
More studies are required to determine whether PAHs other than DBC and BaP are 
immunotoxic in the mouse and, if so, whether that effect involves a similar network of genes. 

Our proposed working model for the short- and long-term consequences of PAH exposure, 
whereby genotoxic stimuli lead to immunotoxicity in the mouse spleen is summarized in Fig. 10. 
Acute exposure to PAH leads to DNA damage, p53-mediated cell cycle arrest and apoptosis, and 
hemolytic anemia. Accumulation of damaged erythrocytes in the red pulp of the spleen, as well 
down-regulation of the pro-apoptotic protein Bnip3l, and activation of anti-apoptotic proteins 
Birc5 and Prc1, as part of a compensatory response to red blood cell loss, are hypothesized to 
lead to increased erythropoiesis, and extramedullary hematopoiesis in the spleen, thus 
contributing to splenomegaly. Other hypotheses such as the potential involvement of heparan-
mediated regulation of the control of stem and progenitor cell fate of the splenocytes by growth 
factors are also suggested by the toxicogenomic data. In addition, we highlighted important roles 
for CYP1B1 and Bnip3l in spleen atrophy and splenomegaly, which can be explored further to 
determine if/how they are responsible for long-lasting compensatory responses to spleen atrophy, 
leading to splenomegaly even months after PAH exposure as seen here with BaP. Finally, we 
demonstrate the utility of toxicogenomics in quantitative health risk assessment of 
immnotoxic/genotoxic chemicals. 
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FIGURE LEGENDS 
FIG. 1. Schematic of DBC metabolic activation leading to the ultimate genotoxic carcinogen 
DBC-11,12-diol-13,14-epoxide and potential mechanism of its immunotoxicity. Structures are 
redrawn from ('	
).. DBC needs to be metabolically activated in order to become a 
carcinogen; this is primarily carried out by cytochrome P450 (CYP1B1). In addition, DBC 
activation and resulting immunotoxicity is mediated by microsomal epoxide hydrolase (mEH) 
(reviewed in &   	
)). DNA damage-mediated p53 induction may result in 
transcriptional modulation of the genes involved in DNA repair, apoptosis, and cell cycle arrest, 
whose function is important for the immune system. 
FIG. 2. DBC induces spleen atrophy in Muta™Mouse males. Animals were treated with 
DBC for 3 consecutive days and spleen weight was determined 4, 24, or 72 h after the last 
exposure. Shown are means ± standard error of the mean of five animals (A) and representative 
pictures of spleens for the high dose 72 h post-treatment (B). Differences from controls are 
indicated as * and ** (p < 0.05 and p < 0.001, respectively). 
FIG. 3. Time- and dose-dependent formation of DBC-DNA adducts in the spleen (A) or bone 
marrow (B) of Muta™Mouse males treated with DBC and measured 4, 24, and 72 h post-
exposure. Error bars represent standard error of the mean of four to five mice (each DNA sample 
was analyzed in two independent 32P-postlabeling assays). ND, not detected. Differences from 
controls are indicated as *** (p < 0.0001). 

FIG. 4. LacZ mutant frequency in the spleen and bone marrow of Muta™Mouse males dosed 
with DBC and measured at 72 h post-exposure. Error bars represent standard error of the mean 
of five mice. Differences from controls are indicated as ** and *** (p < 0.001 and p < 0.0001, 
respectively). 
FIG. 5. Frequency of micronucleated reticulocytes (% MN-RET) and micronucleated 
normochromatic erythrocytes (% MN-NCE) (A) and % reticulocytes (B) in DBC-exposed 
Muta™ Mouse males. Error bars represent the standard error of the mean of measurement from 
five animals. Differences from controls are indicated as * and *** (p < 0.05 and p < 0.0001, 
respectively). 
FIG. 6. Detection of the DNA oxidation marker 8-oxo-dG in the spleens of DBC-exposed 
Muta™ Mouse males. Error bars represent the standard error of the mean of measurement from 
four or five separate animals. Difference from the control is indicated as * (p < 0.05). 
FIG. 7. Negative correlation between spleen profiles of DBC-induced spleen atrophy and 
splenomegaly in mouse due to Bnip3l knock-out. NextBio identified a significant overlap and 
negative correlation between gene expression changes in the spleens of DBC exposed mice 
relative to controls (Bioset 1: our study) and gene expression changes in the spleens of Bnip3l- 
(aka Nix) deficient mice compared to wildtype from *<	

- (Bioset 2). 
FIG. 8. Confirmation of Bnip3l downregulation in DBC-exposed MutaTMMouse spleen by 
immunoblotting. Differences from the controls are indicated as * (p < 0.05, n=3). 
FIG. 9. Identification of genes involved in mediating spleen atrophy and enlargement in the 
MutaTMMouse model in response to PAH exposure. A. Alterations in spleen weight as a result of 
BaP exposure (daily to 100 mg/kg-bw, for 28 days, measured 88 days after the last exposure). B. 

The expression of 10 genes in both spleen atrophy and enlargement models that are hypothesized 
to belong to the same gene network that determines alterations of the spleen size in response to 
PAH exposure. Differences from the controls are indicated as * (p < 0.05, n=3-5). 
FIG. 10. Working model of PAH-induced alterations in spleen size. Under normal 
homeostatic conditions (A), differentiation of hematopoietic progenitor cells into erythrocytes is 
determined by a balance between pro-apoptotic (e.g., Bnip3l) and cell growth and proliferation 
pathways. Genotoxic compounds like DBC and other PAHs activate p53-mediated apoptosis and 
inhibit cell proliferation, leading to reticulocyte (Fig. 4B) and splenocyte loss (measured 
indirectly as spleen atrophy (Fig.1) (B). Prolonged downregulation of Bnip3l and, possibly, other 
pro-apoptotic/tumor suppressors leads to the phenotype, similar to one described in Bnip3l-
defficient mouse *<	

-. That, in combination with increased steady-state levels of 
both normal and damaged erythrocytes that are stored in the spleen, and extramedullary 
hematopoiesis, leads to increased spleen mass following sub-chronic exposure (C). 
SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Fig. 1. Lack of dose-dependent effects of DBC exposure on the liver weight 
in the Muta™Mouse model. * denotes statistically-significant differences from controls (p < 
0.05). 
Supplementary Fig. 2. Representative autoradiographic profiles of DBC-DNA adducts 
detected by 32P-postlabeling in the spleen and bone marrow of the Muta™Mouse exposed to 
DBC. The origin, at the bottom left-hand corner, was cut off before imaging. 
Supplementary Fig. 3. Hierarchical cluster analysis of the DBC-induced alteration in gene 
expression in the spleen of the MutaTMMouse detected by Agilent DNA microarrays 4 or 24 h 

after the last exposure. D0, D1, D2, and D3 indicate control, low, medium, and high doses; T1 
and T2 stand for 4 or 24 h post-exposure; horizontal rows are genes and vertical rows are 
conditions. Animal numbers were added to designate each sample, such that e.g. D3T2_34 
stands for high dose, 24h post-exposure, animal number 34. 
Supplementary Fig. 4. Concordance between DNA microarrays and RNA-Sequencing 
profiling of gene expression in the spleens of Muta™Mouse following DBC exposure.  
Supplementary Fig. 5. Top pathways affected by DBC in the bone marrow and spleen of 
MutaTMMouse are related to cell cycle and aryl hydrocarbon signalling. 
SUPPLEMENTARY FILE LEGEND 
Supplementary File 1. Benchmark dose (BMD) values derived from toxicogenomics data at 
the 10th percentile of all affected genes in the spleen of MutaTMMouse 4 or 24 h after the last 
exposure to DBC for each canonical pathway, containing at least 5 genes that can be modelled 
and with BMD/BMDL < 10. 
SUPPLEMENTARY TABLES 
Supplementary Table 1. Agilent probes affected by the low, medium, and high doses of DBC in the 
spleens of Muta TMMouse males 4 h and 24 h after the last treatment. Probes presented had false 
discovery rate- (FDR)-adjusted p-value < 0.05 and fold change ≥ 1.5 in at least one dose and time point 
(see Gene Expression Omnibus, accession number GSE72334, for all probes). 
Supplementary Table 2. Upstream regulators identified by Ingenuity Pathway Analysis (z-score§ ≥ 
±2.0) in the spleens of MutaTMMouse males dosed with DBC.

Supplementary Table 3. Differentially expressed genes (false discovery rate- (FDR)-adjusted p-
value < 0.05, fold change ≥ 1.5 relative to controls) as identified by RNA-Seq in spleens 4 h after the last 
exposure of MutaTMMouse males to 20.0 mg DBC/kg bw per day.  
Supplementary Table 4. Differentially expressed genes (false discovery rate- (FDR)-adjusted p-
value < 0.05, fold change ≥ 1.5 relative to controls) in bone marrow 24 h after the last exposure of 
MutaTMMouse males to DBC. 
Supplementary Table 5. Upstream regulators identified by Ingenuity Pathway Analysis (z-score§ ≥ 
2.0) in the bone marrow of MutaTMMouse males exposed to DBC.  
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TABLES 
 TABLE 1. Function of the eighteen genes that were perturbed by all doses of DBC in the spleens of MutaTMMouse. 
Gene name Entrez 
gene ID 
Entrez gene name Function (if known) References 
4921504E06Rik 70909 RIKEN cDNA 
4921504E06 gene 
    
BNIP3L 100043
324|121
77 
BCL2/adenovirus 
E1B 19kDa 
interacting protein 
3-like 
Pro-apoptotic protein; promotes apoptosis during erythropoiesis to 
control red blood cell number and to preferentially eliminate 
abnormal erythrocytes. Mediates mitochondrial clearance by 
autophagy (mitophagy) in erythrocytes. 
*<
	

,*
	
)
?
	
)	 
C20orf144   --     
CCDC42B 546886 Coiled-coil domain containing 42B   
CCNDBP1 17151 Cyclin D-type 
binding-protein 1 
May negatively regulate cell cycle progression by inhibition of the 
cyclin-D1/CDK4 complex, thereby preventing phosphorylation of 
RB1 and blocking E2F-dependent transcription. 
5
	
)
 
EPHB6 13848 EPH receptor B6 Transmembrane proteins receptor for ephrin-B family; influences 
cell adhesion and migration. 
5
	
)
 
FAM220A 67238 Family with 
sequence 
similarity 220, 
member A 
Accelerates dephosphorylation of transcription factor STAT3 
(signal transducer and activator of transcription 3), inhibiting its 
activity. 
%
	
) 
FCHSD1 319262 FCH and double 
SH3 domains 1 
F-actin regulatory protein; development and/or maintenance of the 
F-actin cytoskeleton. 

	
) 
FGF13 14168 fibroblast growth 
factor 13 
Broad mitogenic and cell survival activities: embryonic 
development, cell growth, morphogenesis, tissue repair, tumor 
growth, and invasion. 
5
	
)
 
Gm6792 627821 Predicted gene 6792   
Gm6936 628951 Predicted gene 6936   
TABLE 1. (Continued).

Gm4836 (includes others) --     
MBD5   -- Regulates iron metabolism by regulating gene expression of 
ferritin light chain gene (Ftl1; knock out of MBD5 leads to 
reduced intestinal levels of Ftl1 mRNA). 
5
	
)
9
	
) 
NCOA4 27057 Nuclear receptor 
coactivator 4 
Selective cargo receptor for autophagic turnover of ferritin 
(ferritinophagy); critical for iron homeostasis. 
1
	
) 
PPP1CB 19046 Protein 
phosphatase 1, 
catalytic subunit, 
beta isozyme 
Protein phosphatase; essential for cell division, regulates glycogen 
metabolism, muscle contractility and protein synthesis. Iron-
binding protein. 
5
	
)
 
SOX13 20668 SRY (sex 
determining 
region Y)-box 13 
Regulation of embryonic development and in the determination of 
cell fate. 
5
	
)
 
Stfa3 20863 Stefin A3 Cysteine protease inhibitor; epidermal development and 
maintenance. 
5
	
)
 
YIPF4 67864 Yip1 domain 
family, member 4 
Maintenance of the Golgi structure. 5
	
)
 
 

TABLE 2. Canonical pathways identified by Ingenuity Pathway Analysis as being affected 
by DBC in the spleens of MutaTMMouse and for which activity prediction z-score is 
available. 
Time 
point Dose Pathway p-value* z-score 
4 h low None 
4 h med. None 
4 h high 
Role of BRCA1 in DNA damage response 3.32E-05 -0.6 
Estrogen-mediated S-phase entry 3.64E-05 -1.1 
Cyclins and cell cycle regulation 2.65E-04 -1.4 
Cell cycle: G2/M DNA damage checkpoint regulation 3.87E-04# 2.3 
Cell cycle: G1/S checkpoint regulation 2.01E-03 0.3 
Complement system 4.43E-03 1.3 
Role of CHK proteins in cell cycle checkpoint control 8.01E-03 0.8 
ATM signaling 1.54E-02 -0.4 
Aryl hydrocarbon receptor signaling 1.69E-02 -1.9 
24 h low None   
24 h med. Cell cycle: G2/M DNA damage checkpoint regulation 5.83E-04 1.6 
Cyclins and cell cycle regulation 2.09E-02 -1.3 
24 h high 
Estrogen-mediated S-phase entry 6.64E-05 -1.6 
Cell cycle: G2/M DNA damage checkpoint regulation 3.1E-04 2.1 
Role of BRCA1 in DNA damage response 3.8E-04 -0.7 
Cyclins and cell cycle regulation 4.7E-04 -2.1 
ATM signaling 3.9E-03 -1.1 
Cell cycle: G1/S checkpoint regulation 5.4E-03 1.1 
Aryl hydrocarbon receptor signaling 1.5E-02 -2.1 
Pancreatic adenocarcinoma signaling 1.7E-02 -1.0 
Role of CHK proteins in cell cycle checkpoint control 2.7E-02 0.4 
§Z-score assesses the match of observed and predicted up/downregulation patterns; positive z-score 
indicates activation, negative - inhibition. 
*P-value for Fisher's exact test measuring the overlap of observed and predicted regulated gene sets is 
shown. 
#Shown in bold are values with z-score > 2.0 (default cut-off for activation or inhibition in IPA). 

 
  
TABLE 3. Agilent microarray data for the genes selected for RT-PCR-validation in the MutaTMMouse spleen following 
DBC exposure. 
Agilent probe 
ID 
Gene 
Symbol 
Gene expression 4 h after 3-day  gavage Gene expression 24 h after 3-day gavage 
2.0 mg/kg-bw 6.3 mg/kg-bw 20.0 mg/kg-bw 2.0 mg/kg-bw 6.3 mg/kg-bw 
20.0 mg/kg-
bw 
Fold 
change 
FDR 
p-
value 
Fold 
change 
FDR 
p-
value 
Fold 
change 
FDR 
p-
value 
Fold 
change 
FDR 
p-
value 
Fold 
change 
FDR 
p-
value 
Fold 
change 
FDR 
p-
value 
A_51_P363947 Cdkn1a 1.62* 0.034 1.95 0.000 1.58 0.003 1.27 0.487 1.40 0.156 1.47 0.006 
A_51_P248122 Bbc3 1.40 0.228 1.26 0.579 1.44 0.012 1.42 0.047 1.43 0.041 1.71 0.000 
A_55_P1983768 Birc5 1.19 0.955 -1.53 0.666 -4.10 0.000 -1.62 0.418 -2.28 0.027 -3.76 0.000 
A_55_P1988083 Prc1 1.00 0.999 -1.56 0.564 -3.29 0.000 -1.68 0.207 -2.08 0.011 -3.49 0.000 
A_52_P575771 Mtfr1 1.11 0.955 -1.36 0.521 -2.12 0.000 -1.30 0.490 -1.55 0.056 -1.83 0.002 
A_55_P1961463 Bnip3l -1.88 0.000 -2.64 0.000 -3.98 0.000 -1.85 0.000 -2.25 0.000 -2.56 0.000 
A_55_P2042146 Fech -1.53 0.953 -4.07 0.000 -21.60 0.000 -2.96 0.000 -5.76 0.000 -14.08 0.000 
A_55_P2029687 Hmox1 -1.14 0.953 1.05 0.960 1.19 0.547 -1.11 0.830 -1.03 0.965 1.59 0.014 
A_51_P424338 Nqo1 1.02 0.991 -1.28 0.659 -1.53 0.019 -1.25 0.571 -1.56 0.033 -1.51 0.012 
A_51_P255456 Cyp1b1 1.19 0.953 1.30 0.593 1.44 0.025 1.21 0.625 1.25 0.499 1.48 0.008 
A_55_P2186027 Gapdh 1.08 0.953 1.18 0.666 1.21 0.169 -1.03 0.916 1.02 0.967 -1.02 0.940 
*Values above 1.5-fold change and false-discovery rate- (FDR) adjusted p-value < 0.05 are in bold. 
Gene expression values were normalized to Gapdh. 

TABLE 4. Validation of microarray results by RT-PCR for selected genes in the MutaTMMouse spleen following DBC 
exposure 
Accession 
number 
Gene 
Symbol 
Gene expression 4 h after 3-day  gavage Gene expression 24 h after 3-day gavage 
2.0 mg/kg-bw 6.3 mg/kg-bw 20.0 mg/kg-bw 2.0 mg/kg-bw 6.3 mg/kg-bw 20.0 mg/kg-bw 
Fold 
change@ 
FDR 
p-value 
Fold 
change 
FDR 
p-value 
Fold 
change 
FDR 
p-
value 
Fold 
change 
FDR 
p-
value 
Fold 
change 
FDR 
p-
value 
Fold 
change 
FDR 
p-
value 
NM_007669 Cdkn1a 2.06* 0.006 2.48 0.002 2.36 0.002 2.63 0.028 3.32 0.010 2.24 0.009 
NM_133234 Bbc3 1.54  0.206 1.67 0.072 2.47 0.005 1.64 0.023 1.65 0.007 1.28 0.531 
NM_009689 Birc5 -1.87 0.341 -1.48  0.1480 -4.33 0.023 1.50 0.312 -1.53 0.853 -9.26 0.027 
NM_145150 Prc1 -1.69 0.097 -1.49 0.084 -2.34 0.018 1.27 0.386 -1.23 0.889 -3.26 0.035 
NM_026182 Mtfr1 -1.31 0.277 -1.03 0.414 -1.40 0.007 1.24 0.199 -1.11 0.855 1.26 0.264 
NM_009761 Bnip3l -2.41 0.039 -1.60 0.019 -2.66 0.038 -1.18 0.583 -1.92 0.127 -3.90 0.032 
NM_007998 Fech -3.30 0.008 -4.37 0.000 -9.69 0.001 1.07 0.844 -3.11 0.296 -22.77 0.019 
NM_010442 Hmox1 -1.16 0.243 1.05 0.955 1.48 0.955 1.31 0.096 1.20 0.174 1.23  0.434 
NM_008706 Nqo1 -2.19  0.0009 -2.29 0.027 -5.02 0.012 1.61 0.384 -1.58 0.593 -7.15 0.069 
NM_009994 Cyp1b1 1.19 0.494 1.28 0.277 2.12 0.009 1.32 0.116 1.27 0.211 1.33 0.044 
§With respect to controls for each time point; values were normalized to glyceraldehyde-3-phosphate dehydrogenase (Gapdh; 
NM_008084) expression. 
*Values above 1.5-fold change and false-discovery rate- (FDR) adjusted p-value < 0.05 are in bold. 

TABLE 5. The expression of selected genes measured by microarrays, RT-PCR, and 
RNA-Seq in the spleens of MutaTMMouse 4 h following exposure to 20.0 mg DBC/kg 
bw per day for three days. 
Accession 
number 
Gene 
Symbol 
Microarrays RT-PCR RNA-Seq 
Fold 
change 
FDR p-
value 
Fold 
change 
FDR p-
value 
Fold 
change 
FDR p-
value 
NM_007669 Cdkn1a 1.58* 0.000 2.36 0.002 2.90 0.000 
NM_133234 Bbc3 1.44 0.010 2.47 0.005 4.00 0.000 
NM_009689 Birc5 -1.50 0.000 -4.33 0.023 -5.50 0.000 
NM_145150 Prc1 -3.29 0.000 -2.34 0.018 -6.00 0.000 
NM_026182 Mtfr1 -2.12 0.000 -1.40 0.007 -3.80 0.000 
NM_009761 Bnip3l -3.98 0.000 -2.66 0.038 -3.40 0.000 
NM_007998 Fech -21.6 0.000 -9.69 0.001 -11.80 0.000 
NM_010442 Hmox1 1.19 0.550 1.48 0.955 2.10 0.000 
NM_008706 Nqo1 -1.53 0.020 -5.02 0.012 -4.90 0.000 
NM_009994 Cyp1b1 1.44 0.020 2.12 0.009 -1.04 0.85 
NM_008084 Gapdh 1.21 0.169 1.00 0.000 1.37 0.227 
*Values above 1.5-fold change and false-discovery rate- (FDR) adjusted p-value < 0.05 
are in bold. 

TABLE 6. Comparison of the expression of selected genes in the spleen and the bone marrow of MutaTMMouse 24 h 
following three-day exposure to DBC. 
Accession 
number 
Gene 
Symbol 
Spleen Bone Marrow 
2.0 mg/kg-bw 6.3 mg/kg-bw 20.0 mg/kg-bw 2.0 mg/kg-bw 6.3 mg/kg-bw 
20.0 mg/kg-
bw 
Fold 
change 
FDR 
p-
value 
Fold 
change 
FDR 
p-
value 
Fold 
change 
FDR 
p-
value 
Fold 
change 
FDR 
p-
value 
Fold 
change 
FDR 
p-
value 
Fold 
change 
FDR 
p-
value 
NM_007669 Cdkn1a 1.27 0.487 1.40 0.156 1.47 0.006 6.27 0.000 10.63 0.000 22.78 0.000 
NM_133234 Bbc3 1.42 0.047 1.43 0.041 1.71 0.000 1.28 0.858 1.65 0.283 2.68 0.001 
NM_009689 Birc5 -1.62 0.418 -2.28 0.027 -3.76 0.000 1.10 0.921 -1.04 0.942 -1.45 0.186 
NM_145150 Prc1 -1.68 0.207 -2.08 0.011 -3.49 0.000 1.08 0.933 -1.20 0.590 -1.72 0.019 
NM_026182 Mtfr1 -1.30 0.490 -1.55 0.056 -1.83 0.002 1.17 0.862 -1.19 0.674 -1.73 0.038 
NM_009761 Bnip3l -1.85 0.000 -2.25 0.000 -2.56 0.000 1.12 0.922 1.12 0.846 -1.36 0.388 
NM_007998 Fech -2.96 0.000 -5.76 0.000 -14.08 0.000 1.23 0.848 1.04 0.959 -1.35 0.425 
NM_010442 Hmox1 -1.11 0.830 -1.03 0.965 1.59 0.014 1.55 0.515 1.56 0.183 3.20 0.000 
NM_008706 Nqo1 -1.25 0.571 -1.56 0.033 -1.51 0.012 -1.56 0.735 -1.30 0.719 -1.51 0.436 
NM_009994 Cyp1b1 1.21 0.625 1.25 0.499 1.48 0.008 1.63 0.550 1.45 0.446 2.95 0.000 
NM_008084 Gapdh -1.03 0.916 1.02 0.967 -1.02 0.940 1.03 0.993 1.11 0.874 1.29 0.501 
*Values above ± 1.5-fold change and false-discovery rate- (FDR) adjusted p-value < 0.05 are in bold. 

TABLE 7. Benchmark dose (BMD) values derived from toxicogenomics data at the 10th 
percentile of all affected genes in the spleen of MutaTMMouse in: (a) each canonical pathway 
activated or inhibited (z-score  2.0), (b) network comprising most sensitive (affected at all 
doses and time points) genes, or (c) most sensitive pathway 
Time 
post-
treatment 
Ingenuity Pathway Analysis pathway or 
network 
Number of 
genes 
modelled  
BMD*             BMDL         
(mg/kg-bw per day) 
4 h 
Cell cycle: G2/M DNA damage checkpoint 
regulation (a) 17 4.46 2.78 
Cellular growth and proliferation, 
hematological system development & 
function, hematopoiesis network (b) 7 0.71 0.35 
Calcium signaling (c) 45 2.20 0.25 
24 h 
Cell cycle: G2/M DNA damage checkpoint 
regulation (a) 13 1.69 0.07 
Cyclins and cell cycle regulation (a) 25 1.07 < 0.02 
Aryl hydrocarbon receptor signaling (a) 37 1.86 0.20 
Cellular growth and proliferation, 
hematological system development & 
function, hematopoiesis network (b) 15 0.17 0.080 
Heparan sulfate biosynthesis (c) 8 0.066 0.025 
¶Similar to 9	
)), but examined lowest BMDLs at the 10th percentile rather than 
lowest median BMDLs. 
*BMD and BMDL (lower confidence limit on BMD) were calculated with default benchmark 
response of one standard deviation. 
@Lowest BMDL values for each approach (a, b, or c) are in bold (provided BMD/BMDL > 10). 
Note: BMD(L) values that were less than 1% of the lowest dose administered (i.e., 0.02 mg/kg bw 
per day) and/or those that produced BMD/BMDL ratio > 10.0 (indicative of poor fit) were not 
considered. 
 

TABLE 8. Comparison of BMD values derived from toxicogenomis (lowest BMDLs for each of toxicogenomics 
approach presented in Table 7) and apical (spleen weight) data with potential relevance to health risk assessment 
of DBC. 
Time 
post-
treatment 
Most sensitive toxicogenomic endpoints Transcriptional 
BMDL (mg/kg-bw 
per day) 
Apical (spleen weight) 
BMDL (mg/kg-bw per 
day) 
4 h None (all most sensitive pathways come from 24-hr time 
point) 
  0.095 
24 h 
Aryl hydrocarbon receptor signaling pathway 0.204 
4.44 
Cellular growth and proliferation, hematological system 
development & function, hematopoiesis network 0.080 
Heparan sulfate biosynthesis pathway 0.025

 
72 h None (see above)   0.707 
¶Corresponding benchmark dose (BMD) value is 0.257 mg/kg-bw per day, making BMD/BMDL ratio equal to 2.7. 
@BMDL values for toxicogenomics and spleen weight data that are the lowest and thus proposed as PODs for DBC-
mediated immunotoxicity are in bold. 
Note: BMD(L) were calculated with default benchmark response of one standard deviation. 

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